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y In the landmark phase 3 ABC-02 trial, Valle and 
colleagues1 established the combination of gemcitabine 
and cisplatin as the standard of care for ﬁ rst-line 
treatment of patients with advanced biliary tract 
cancer. This regimen showed a median overall survival 
of nearly 1 year, and based on this encouraging result, 
the combination of gemcitabine and platinum has 
emerged as the chemotherapy backbone for testing 
the addition of targeted treatments. Unfortunately, 
trials combining an anti-VEGF agent or an anti-EGFR 
agent with gemcitabine and platinum have yielded 
disappointing results,2–6 but similar eﬀ orts with agents 
targeting alternative pathways are underway. With 
insuﬃ  cient eﬀ ective second-line systemic regimens in 
advanced biliary tract cancer, enhancing the eﬃ  cacy 
of ﬁ rst-line treatment is a rational strategy to improve 
patient outcomes in this aggressive disease.
In The Lancet Oncology, Valle and colleagues7 report the 
results of the ABC-03 trial, a randomised phase 2 trial 
of gemcitabine and cisplatin with or without cediranib 
in the ﬁ rst-line treatment of patients with advanced 
biliary tract cancer. Cediranib is an oral potent inhibitor 
of the VEGF receptor tyrosine kinases. The strategy of 
simultaneously targeting the tumour microenvironment 
with antiangiogenic treatment and tumour cells 
with chemotherapy has improved patient survival in 
advanced colon, lung, gastric, and ovarian cancers. 
However, similar to other trials of anti-VEGF treatment 
in advanced biliary tract cancer, the ABC-03 trial was 
negative and ﬁ ndings showed no diﬀ erence in the 
primary endpoint, progression free survival, between the 
two groups (HR 0·93, 95% CI 0·65–1·35; p=0·72). 
Why did the addition of cediranib fail in this context? 
First, the combination of chemotherapy with kinase 
inhibitors of VEGF pathway have largely been ineﬀ ective 
across disease types and have not matched the eﬃ  cacy 
of anti-VEGF and anti-VEGFR antibodies in a similar 
setting. These ﬁ ndings might be due to diﬀ erential 
mechanisms of action and increased oﬀ -target eﬀ ects 
with kinase inhibitors.
Second, the lack of validated predictive biomarkers 
for the identiﬁ cation of patients likely to beneﬁ t from 
cediranib led to an unselected study population. Most 
previous clinical trials including anti-VEGF agents 
in advanced biliary tract cancer were also done in 
unselected populations and have not reported analysis 
of VEGF-related biomarkers. A randomised phase 2 trial8 
of gemcitabine with or without sorafenib showed that 
PDGFR-β expression in tumour stroma was associated 
with improved progression-free survival, but this result 
has not been further validated. Similarly, studies of 
cediranib in other cancers have not shown consistent 
predictive biomarkers that could be used for future 
trials. Valle and colleagues should be commended for 
reporting circulating biomarker analysis in the largest 
cohort of patients with advanced biliary tract cancer in 
a trial of antiangiogenic treatment so far. Additional 
data for outcomes by anatomic location might also yield 
hypotheses regarding subpopulations likely to beneﬁ t 
from cediranib.
Third, the toxic eﬀ ects of cediranib could have limited 
drug exposure. Frequencies of grade 3 and 4 adverse 
events related to VEGFR inhibition were signiﬁ cantly 
higher in the cediranib group than the placebo group 
including hypertension and diarrhoea. Patients who 
received  cediranib more frequently required at least 
one dose reduction compared with  placebo from the 
already attenuated dose of 20 mg once a day.
Fourth, VEGF inhibition could have paradoxically 
fuelled tumour growth and led to chemoresistance. 
Although objective responses were more common in the 
cediranib group than in the placebo group, the duration 
of response was longer in the placebo group. Several 
explanations could account for this, including random 
statistical error, but one explanation could be that 
cediranib-induced vascular pruning initially led to tumour 
regression but the ensuing hypoxia ultimately promoted 
tumour progression. Increasing evidence has shown that 
hypoxia can create a hostile environment that promotes 
tumour growth by inducing angiogenesis, genetic 
instability, cancer cell invasion, stem-like phenotype, 
epithelial-to-mesenchymal transition, and resistance to 
apoptosis.9 The success of antiangiogenic drugs could 
rest on achieving balance between therapeutic and 
pathological angiogenesis in which tumour vascular 
normalisation rather than vascular pruning is the goal. In 
view of the negative results of several anti-VEGF agents 
in advanced biliary tract cancer, future eﬀ orts with 
randomised trials should aim to use alternative strategies 
(eg, anti-VEGFR antibodies), inhibit alternative targets 
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in angiogenesis, or use a biomarker-driven trial design to 
select patients likely to beneﬁ t from this strategy.
Two merits of the ABC-03 trial deserve comment. First, 
the researchers are to be commended for requiring a high 
threshold of activity to declare the trial positive. With less 
than 5% of positive phase 2 combination therapy trials 
eventually improving the standard of care in oncology,10 
aiming for a large eﬀ ect size can ultimately save resources 
and protect patients from receiving ineﬀ ective, toxic 
regimens in futile phase 3 trials. However, the design of 
a robust randomised phase 2 trial can necessitate a large 
sample size, a challenge in a rare cancer like advanced 
biliary tract cancer. The ABC investigators addressed 
this issue with their second merit: collaboration. 
The consortium they have developed in the UK allowed 
them to accrue 124 patients across 14 centres in 
18 months and collect blood for biomarker analysis from 
many of these patients. This structure can serve as a 
model for other countries to execute eﬃ  cient trials with 
generalisable results in advanced biliary tract cancer.
In conclusion, gemcitabine and platinum will remain the 
standard ﬁ rst-line treatment  for patients with advanced 
biliary tract cancer. Further eﬀ orts to characterise the 
biology of both the tumour and its microenvironment in 
advanced biliary tract cancer, coupled with well-designed 
clinical trials, will hopefully bring us closer to ﬁ nding the 
next eﬀ ective treatment in this disease.  
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Is the beneﬁ t of oxaliplatin in rectal cancer clinically relevant?
The statement “a statistically signiﬁ cant gain is not 
necessarily clinically relevant” is accepted by most. 
Statistical signiﬁ cance is an objective ﬁ nding, dependent 
on the quality of the trial, whereas the assessment of 
clinical relevance is subjective and open for discussion.
In The Lancet Oncology, Claus Rödel and colleagues1 report 
the results of a phase 3 trial examining oxaliplatin added 
to ﬂ uorouracil-based preoperative chemoradiotherapy 
and postoperative chemotherapy in locally advanced 
rectal cancer. The study was a large, well performed trial, 
meticulously analysed by a group with an excellent track 
record; thus, the statistical signiﬁ cance favouring the 
addition of oxaliplatin is likely true. To assess its clinical 
relevance, the design of the study (eg, inclusion criteria 
and choice of control treatment) and the magnitude of the 
gain must be considered in relation to present knowledge. 
At 3 years, the absolute gain in the primary trial 
endpoint, disease-free survival, was 4·7% and the 
absolute gain for distant recurrences was 3·9%. 
The target of clinical relevance was to decrease distant 
recurrences. It is not known if these gains are caused 
by the addition of preoperative or postoperative 
oxaliplatin, or by both. The controversial issue of the 
value of adjuvant chemotherapy in rectal cancer after 
preoperative (chemo)radiotherapy2,3 has not come 
closer to a solution. The diﬀ erent ﬂ uoropyrimidine 
schedules in the experimental and control groups 
prevent an assessment of the eﬃ  cacy and toxic eﬀ ects 
of oxaliplatin. The lack of any diﬀ erence in toxic eﬀ ects 
to the postoperative therapies probably reﬂ ects the 
choice of the “toxic” Mayo clinic schedule as control 
therapy; if a proper infusion schedule had been chosen, 
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